StreetInsider.com News Articles

Form EFFECT GT Biopharma, Inc.

Wed, 21 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261021/27212524.html

Form 424B3 GT Biopharma, Inc.

Tue, 20 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261020/27211308.html

Form DEF 14A GT Biopharma, Inc. For: Oct 13

Tue, 13 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261013/27181812.html

Form S-1 GT Biopharma, Inc.

Fri, 09 Oct 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20261009/27172397.html

Form PRE 14A GT Biopharma, Inc. For: Oct 02

Fri, 02 Oct 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20261002/27143668.html

Form D GT Biopharma, Inc.

Tue, 29 Sep 2026 13:06:00 -0400

si-local-file:///var/storage/secattach/20260929/27120725.html

Form 8-K GT Biopharma, Inc. For: Sep 22

Fri, 25 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260925/27107472.html

Form 8-K GT Biopharma, Inc. For: Sep 18

Mon, 21 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260921/27085451.html

Form SCHEDULE 13G GT Biopharma, Inc. Filed by: RainForest Partners, LLC

Tue, 15 Sep 2026 19:35:00 -0400

si-local-file:///var/storage/secattach/20260915/27066164.html

GT Biopharma receives FDA clearance for GTB-5550 IND in multiple myeloma

Tue, 15 Sep 2026 09:15:24 -0400

GT Biopharma, Inc. (NASDAQ: GTBP) announced that the FDA has cleared an investigational new drug (IND) application for GTB-5550, its B7-H3-targeted natural killer cell engager, in multiple myeloma. The clearance was granted under an investigator-sponsored trial protocol.

The planned Phase 1a/1b trial, described by the company as the first-in-human study of a B7-H3-targeted TriKE in multiple myeloma, will use subcutaneous administration. The Phase 1a dose escalation portion will enroll patients who have received at least four prior lines of therapy and evaluate up to six dose cohorts to identify the maximum tolerated dose. The Phase 1b expansion cohort will subsequently enroll

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

Tue, 15 Sep 2026 09:15:00 -0400

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol

Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding

Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026

Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway into Q3 2027

SAN FRANCISCO, CALIFORNIA, Sept. 15, 2026 (GLOBE NEWSWIRE)

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

Tue, 15 Sep 2026 09:15:00 -0400

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol

Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding

Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026

Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway into Q3 2027

SAN FRANCISCO, CALIFORNIA, Sept. 15, 2026 (GLOBE NEWSWIRE)

Form 8-K GT Biopharma, Inc. For: Sep 14

Tue, 15 Sep 2026 08:58:00 -0400

si-local-file:///var/storage/secattach/20260915/27061941.html

GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

Fri, 11 Sep 2026 08:00:00 -0400

SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE^® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.

The webinar will feature Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, and Dr. Jeffrey Miller, MD¹, Consulting Senior Medical Director, who will discuss clinical progress in blood cancers

GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

Fri, 11 Sep 2026 08:00:00 -0400

Form 8-K GT Biopharma, Inc. For: Aug 14

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931595.html

Form 8-K GT Biopharma, Inc. For: Aug 14

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931595.html

Form 10-Q GT Biopharma, Inc. For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924858.html

Form 10-Q GT Biopharma, Inc. For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924858.html

GT Biopharma Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE^® remains ongoing, with an update anticipated in 2H 2026

Phase 1 basket trial evaluating GTB-5550 TriKE^®in multiple solid tumor types known to express B7-H3 initiated May 2026 with an update anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts

Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins, supporting the anticipation of multiple new development candidates moving towards pre-IND development in 2027

Cash balance as of June 30, 2026 of approximately $5.1 million anticipated to provide

GT Biopharma Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE^® remains ongoing, with an update anticipated in 2H 2026

Phase 1 basket trial evaluating GTB-5550 TriKE^®in multiple solid tumor types known to express B7-H3 initiated May 2026 with an update anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts

Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins, supporting the anticipation of multiple new development candidates moving towards pre-IND development in 2027

Cash balance as of June 30, 2026 of approximately $5.1 million anticipated to provide

Form DEF 14A GT Biopharma, Inc. For: Jul 02

Thu, 02 Jul 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260702/26728439.html

Form DEF 14A GT Biopharma, Inc. For: Jul 02

Thu, 02 Jul 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260702/26728439.html

Form PRE 14A GT Biopharma, Inc. For: Jun 18

Thu, 18 Jun 2026 16:46:00 -0400
si-local-file:///var/storage/secattach/20260618/26666806.html

Form PRE 14A GT Biopharma, Inc. For: Jun 18

Thu, 18 Jun 2026 16:46:00 -0400
si-local-file:///var/storage/secattach/20260618/26666806.html